Skip to main content
padlock icon - secure page this page is secure

Phase I study of domatinostat (4SC‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

Buy Article:

$59.00 + tax (Refund Policy)

Domatinostat (4SC‐202) is a selective class I histone deacetylase inhibitor (HDACi). This phase I study investigated safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity in patients with advanced hematological malignancies.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 4SC‐202; HDAC inhibition; domatinostat; epigenetics; hematological malignancies; phase I study

Document Type: Research Article

Publication date: February 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more